RxDoctor Payments Data

Brendan Gilmore, MD

Hematology & Oncology · Chicago, ILNPI 1619396231

Payments from drug & device makers

$4,908in general payments, 2019–2025

Across 51 payments — averaging $96.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novartis$176
  • Bristol Myers Squibb$155
  • Pfizer$106
  • Sobi, Inc$100
  • Merck$98
  • plus $502 from 14 others

What the payments were for

  • Consulting fees$3,60073%
  • Food & beverage$1,19624%
  • Education$1122%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,908 in reported general payments places this provider in the 45th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$106,044
Medicare patients
269
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate11$286,227
KisqaliRibociclib Succinate13$211,029
IbrancePalbociclib13$205,318
BrukinsaZanubrutinib20$169,710
CalquenceAcalabrutinib Maleate15$151,774
Abiraterone Acetate52$108,033
ThalomidThalidomide13$64,075
EliquisApixaban71$55,497
Erlotinib Hcl11$4,004
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,218
Letrozole78$1,652
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$1,299
Imatinib Mesylate13$963
Tamoxifen Citrate37$793
Ondansetron Hcl37$442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$106$260,81484 claims
NovartisKisqali$176$211,02913 claims
AstraZenecaCalquence$3,772$151,77415 claims
Bristol Myers SquibbThalomid$155$64,07513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →